menu
    • menu
    [{"orgOrder":0,"company":"Alopexx Oncology","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"AV0328","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Alopexx Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alopexx Oncology \/ Bharat Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Alopexx Oncology \/ Bharat Biotech"},{"orgOrder":0,"company":"Alopexx Oncology","sponsor":"Biotech Consortia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Financing","leadProduct":"AV0328","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Alopexx Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alopexx Oncology \/ Biotech Consortia","highestDevelopmentStatusID":"7","companyTruncated":"Alopexx Oncology \/ Biotech Consortia"},{"orgOrder":0,"company":"Alopexx Oncology","sponsor":"Beijing Shenogen Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"DI-LEU16-IL2","moa":"CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Alopexx Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alopexx Oncology \/ Beijing Shenogen Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Alopexx Oncology \/ Beijing Shenogen Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Alopexx Oncology

    Menu

    Alopexx Oncology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Alopexx Oncology

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Alopexx Oncology

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AV0328

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase I/ Phase II

    Sponsor : Bharat Biotech

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Alopexx Collaborates with Bharat Biotech on Anti-Microbial Vaccine AV0328

    Details : The collaboration aims for the co-development and commercialization of Alopexx’s proprietary broad-spectrum anti-microbial vaccine, AV0328, in India and other low and lower middle-income countries.

    Product Name : AV0328

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    October 09, 2024

    Lead Product(s) : AV0328

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I/ Phase II

    Sponsor : Bharat Biotech

    Deal Size : Undisclosed

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Alopexx Oncology

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Alopexx Oncology

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AV0328

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase I/ Phase II

    Sponsor : Biotech Consortia

    Deal Size : Undisclosed

    Deal Type : Financing

    DEALS_DEV arrow-down

    Alopexx Announces Investment from Biotech Consortia, Inc.

    Details : The investment from BCI will be crucial for the advancement of AV0328, a synthetic vaccine designed to target poly N-acetyl glucosamine, and all clinical programs at Alopexx.

    Product Name : AV0328

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    June 09, 2024

    Lead Product(s) : AV0328

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I/ Phase II

    Sponsor : Biotech Consortia

    Deal Size : Undisclosed

    Deal Type : Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Alopexx Oncology

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Alopexx Oncology

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : DI-LEU16-IL2

    Therapeutic Area : Oncology

    Study Phase : Phase II

    Sponsor : Beijing Shenogen Pharma

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Alopexx Oncology Announces Licensing Agreement with Beijing Shenogen Pharma

    Details : The deal facilitates development and commercialization of DI-Leu16-IL2 in China and other parts of Asia.

    Product Name : DI-LEU16-IL2

    Product Type : Antibody

    Upfront Cash : Undisclosed

    March 03, 2020

    Lead Product(s) : DI-LEU16-IL2

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Sponsor : Beijing Shenogen Pharma

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth